Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
The closing price of Spyre Therapeutics Inc (NASDAQ: SYRE) was $12.67 for the day, up 2.01% from the previous closing price of $12.42. In other words, the price has increased by $2.01 from its previous closing price. On the day, 0.74 million shares were traded. SYRE stock price reached its highest trading level at $12.78 during the session, while it also had its lowest trading level at $12.25.
Ratios:
Our analysis of SYRE’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 11.26 and its Current Ratio is at 11.26. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Leerink Partners on April 08, 2025, initiated with a Outperform rating and assigned the stock a target price of $45.
On March 18, 2025, Wolfe Research started tracking the stock assigning a Outperform rating and target price of $27.
On September 04, 2024, Wedbush started tracking the stock assigning a Outperform rating and target price of $45.Wedbush initiated its Outperform rating on September 04, 2024, with a $45 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Nov 06 ’24 when Albers Jeffrey W. sold 6,700 shares for $36.76 per share. The transaction valued at 246,313 led to the insider holds 27,360 shares of the business.
Albers Jeffrey W. sold 300 shares of SYRE for $10,929 on Oct 25 ’24. The Director now owns 34,060 shares after completing the transaction at $36.43 per share. On Oct 25 ’24, another insider, SESSIONS, LLC, who serves as the Director of the company, bought 7,000 shares for $33.70 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SYRE now has a Market Capitalization of 763691840 and an Enterprise Value of 316423360.
Stock Price History:
The Beta on a monthly basis for SYRE is 2.82, which has changed by -0.6194624 over the last 52 weeks, in comparison to a change of 0.05430484 over the same period for the S&P500. Over the past 52 weeks, SYRE has reached a high of $40.49, while it has fallen to a 52-week low of $10.91. The 50-Day Moving Average of the stock is -29.80%, while the 200-Day Moving Average is calculated to be -49.85%.
Shares Statistics:
SYRE traded an average of 703.86K shares per day over the past three months and 989050 shares per day over the past ten days. A total of 60.26M shares are outstanding, with a floating share count of 51.14M. Insiders hold about 15.13% of the company’s shares, while institutions hold 93.79% stake in the company. Shares short for SYRE as of 1743379200 were 11358696 with a Short Ratio of 16.14, compared to 1740700800 on 10022703. Therefore, it implies a Short% of Shares Outstanding of 11358696 and a Short% of Float of 25.56.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
